MOZOBIL (plerixafor) Patient Assistance Program
Don’t let the high cost of brand stem cell mobilization therapy disrupt your treatment. We help eligible patients access Mozobil (plerixafor) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Mozobil (plerixafor) is FDA-approved in combination with granulocyte colony-stimulating factor (G-CSF, filgrastim or biosimilars) for mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplantation in adults with non-Hodgkin lymphoma (NHL) and multiple myeloma.
- Without assistance, Mozobil costs commonly run approximately $9,000–$12,000 per dose (single 24 mg vial; multiple doses may be needed).
- Through AffordMyPrescriptions, qualifying patients can access Mozobil for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Mozobil in the U.S. as of 2026. Mozobil is added to G-CSF mobilization for patients with inadequate stem cell mobilization on G-CSF alone (about 25–30% of NHL/MM patients). G-CSF (filgrastim with biosimilars Granix, Nivestym, Zarxio, Releuko; pegfilgrastim with biosimilars Fulphila, Udenyca, Ziextenzo, Stimufend, Fylnetra) is widely available.
What Is Mozobil Prescription Assistance Program?
The Mozobil Prescription Assistance Program is a manufacturer-sponsored initiative that provides Mozobil at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for autologous stem cell transplant patients who are uninsured or underinsured, as well as Medicare Part B/D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology/transplant coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through coordination with your transplant team.
Pharmacy Price Comparison
- Without assistance, Mozobil costs roughly $9,000–$12,000 per single dose vial. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$11,500/dose | Save substantially |
| CVS Pharmacy | ~$12,000/dose | Save substantially |
| Walmart | ~$9,500/dose | Save substantially |
| Costco | ~$9,200/dose | Save substantially |
Specialty Pharmacy | ~$10,000/dose | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Mozobil Prescription Program?
The Patient Assistance Program is free to apply for and provides Mozobil at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Mozobil:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $9,000–$12,000 per dose per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Mozobil assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Mozobil Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Mozobil:
Mozobil (plerixafor) is a CXCR4 antagonist used in combination with G-CSF to mobilize hematopoietic stem cells from the bone marrow into the peripheral blood — where they can be collected by apheresis for use in autologous stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
How Mozobil Works:
Hematopoietic stem cells are normally held inside the bone marrow through specific bonding interactions between CXCR4 receptors and SDF-1 proteins. For an autologous stem cell transplant, these cells must be collected from the peripheral blood, where very few normally circulate. While standard G-CSF therapy breaks this bond modestly to release cells, many patients with extensive prior chemotherapy fail to mobilize enough cells on G-CSF alone. Mozobil directly blocks the CXCR4 receptor, dramatically releasing a massive wave of stem cells into the bloodstream within hours and boosting collection yields by three to four fold.
Form and use:
Mozobil is administered as a subcutaneous injection precisely 11 hours before a patient’s scheduled apheresis collection procedure. This medication is given after the patient has already completed four consecutive days of G-CSF priming therapy, which continues for the duration of the mobilization process. The standard dosage is 0.24 mg/kg of body weight, capped at a maximum of 40 mg for individuals weighing 83 kg or more. Healthcare providers can administer up to four consecutive daily doses if needed to successfully harvest the target number of stem cells.
Generic availability:
As of 2026, there is no generic version of Mozobil available for patients within the United States. In contrast, the G-CSF products required for the initial priming phase, such as filgrastim and pegfilgrastim, have multiple lower-cost biosimilars available compared to the original Neupogen and Neulasta brands. As an alternative to the G-CSF and Mozobil regimen, some academic treatment centers utilize chemo-mobilization protocols. This alternative strategy combines cyclophosphamide with G-CSF to achieve the necessary stem cell release, and patients should discuss these options directly with their transplant team.
Warnings:
Mozobil carries an explicit warning against use in leukemia patients due to the dangerous risk of mobilizing leukemia cells directly into the bloodstream. It can also cause or contribute to thrombocytopenia, a condition marked by low blood platelet counts, as well as rare cases of hyperleukocytosis. Additional class-related warnings shared with G-CSF include splenic enlargement and the potential for a rare, life-threatening splenic rupture. Finally, the medication can trigger severe allergic reactions, anaphylactic shock, and presents risks for embryo-fetal toxicity.
FAQ (Frequently Asked Questions)
How Much Does Mozobil Cost Without Insurance?
Mozobil costs approximately $9,000–$12,000 per dose. Most patients need 1–4 doses for adequate stem cell collection — total Mozobil cost commonly $9,000–$48,000+. Through AffordMyPrescriptions, qualifying patients receive Mozobil at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Why Do I Need Mozobil If G-CSF Alone Should Work?
About 25–30% of patients fail to mobilize adequate stem cells with G-CSF alone — risk factors include extensive prior chemotherapy (especially lenalidomide, melphalan, fludarabine), prior radiation to marrow-rich areas, older age, and multiple prior lines of therapy. For these ‘poor mobilizers,’ adding Mozobil to G-CSF dramatically increases mobilization success — salvaging the transplant plan that would otherwise be jeopardized
How Does The Schedule Work?
Day -4 to Day 0 (apheresis day): daily G-CSF injections to prime mobilization. On day -1 (evening before apheresis): Mozobil given subcutaneously ~11 hours before apheresis. On day 0: apheresis collection in the morning, with G-CSF continued. If collection target not achieved, Mozobil and G-CSF may be continued daily for up to 4 days of apheresis. Your transplant team coordinates the exact schedule.
What Are The Common Side Effects?
Most common: injection-site reactions, diarrhea, nausea, fatigue, headache, joint pain. Less common: hypersensitivity reactions, tachycardia/palpitations, dizziness, orthostatic hypotension. Most side effects are mild and resolve quickly. Tell your team about any concerning symptoms.
Can I Get Mozobil Through The PAP If I Have Medicare?
Yes. Mozobil is typically billed through Medicare Part D (or sometimes Part B depending on administration setting); the PAP can help with copays or for patients without insurance. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What About Chemo-Mobilization Instead?
Some transplant centers use chemo-mobilization (cyclophosphamide followed by G-CSF) as an alternative mobilization strategy — particularly in patients with active disease who could benefit from cytoreduction. Chemo-mobilization can achieve high CD34+ cell yields but carries chemo-related toxicity. G-CSF + plerixafor is generally well-tolerated and effective for most poor mobilizers. Discuss with your transplant team.
What If My Application Is Denied?
If denied, we explore alternatives — appealing through your insurance, switching to chemo-mobilization regimens if appropriate, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Leukemia & Lymphoma Society, Multiple Myeloma Research Foundation, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Mozobil, our team may be able to help you access assistance programs designed to make brand stem cell mobilization therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.